**ACCRELIST LTD. (亚联盛控股公司)**

(Company Registration No. 198600445D)
(Incorporated in the Republic of Singapore)

---

**ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES**

---

The Board of Directors (the "**Board**") of Accrelist Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that the following transactions that occurred during the financial period ended 30 September 2022 and up to the date of the announcement, pursuant to Rule 706A of the SGX-ST Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**"):-

**INCREASE IN PAID-UP CAPITAL OF INDIRECT WHOLLY-OWNED SUBSIDIARIES, ACCRELIST MEDICAL AESTHETICS (CENTRAL@CLARKE QUAY) PTE. LTD. AND ACCRELIST MEDICAL AESTHETICS (ORCHARD CENTRAL) PTE. LTD.**

Accrelist Medical Aesthetics (BM) Pte. Ltd., a wholly-owned subsidiary of the Company, had on 13 October 2022 increased the issued and paid-up share capital of both its wholly-owned subsidiaries, Accrelist Medical Aesthetics (Central@Clarke Quay) Pte. Ltd. and Accrelist Medical Aesthetics (Orchard Central) Pte. Ltd., from S$10,000 to S$100,000 by way of allotment and issuance of additional 90,000 ordinary shares in cash, at S$1.00 per share (the "**Transaction**").

The Transaction is not expected to have any material impact on the net tangible assets and earnings per share of the Company for the current financial year ending 31 March 2023.

None of the directors, substantial shareholders or controlling shareholders of the Company have any interests, direct or indirect, in the aforesaid Transaction, save for their shareholding interests in the Company.

**COMPLETION OF DISPOSAL OF OZHEAN ACCRELIST AESTHETICS SDN BHD**

Accrelist Medical Aesthetics (BM) Pte. Ltd., a wholly-owned subsidiary of the Company, had on 29 November 2022, entered into a conditional Sale and Purchase Agreement (the "**Agreement**") with Ozhean Sdn Bhd (the "**Purchaser**") for the sale of 490,000 ordinary shares in the capital of Ozhean Accrelist Aesthetics Sdn Bhd ("**Ozhean Accrelist Aesthetics**"), representing 49% of the issued and fully paid-up capital of Ozhean Accrelist Aesthetics (the "**Proposed Share Disposal**").

Following the announcement on 29 November 2022, the Proposed Share Disposal was completed on 6 January 2023 and the 490,000 ordinary shares of Ozhean Accrelist Aesthetics have been transferred to the Purchaser in accordance with the terms and conditions of the Agreement.

None of the directors, substantial shareholders or controlling shareholders of the Company have any interests, direct or indirect, in the aforesaid Proposed Share Disposal, save for their shareholding interests in the Company.

**UPDATES ON ACCRELIST MEDICAL AESTHETICS (SPC) PTE. LTD.**

As announced on 10 September 2021, the Company had entered into a shareholders' agreement (the "**SHA**") with Dame Dato Sri Marilyn Tay Bee Choo (the "**Investor**") in relation to the proposed investment of S$1,000,000 (the "**Consideration**") in its wholly owned subsidiary, Accrelist Medical Aesthetics (SPC) Pte. Ltd. ("**A.M Aesthetics SPC**"), through the purchase of 30,000 shares from the Company (the "**Sale Shares**"), representing 30% of the total issued and paid-up capital of A.M Aesthetics SPC (the "**Proposed Transaction**").

As of the date of this announcement, the Proposed Transaction has not been completed. The Consideration has not been received and the Company is still holding 100% of shares of A.M Aesthetics SPC. The Company will make further announcements as and when there are further updates and material developments in relation to the Proposed Transaction.

**BY ORDER OF THE BOARD**

Dr. Terence Tea
Executive Chairman and Managing Director

13 January 2023

---

*This Announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, RHT Capital Pte. Ltd. ("**Sponsor**") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**").*

*This Announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this Announcement, including the correctness of any of the statements or opinions made or reports contained in this Announcement.*

*The contact person for the Sponsor is: Mr Mah How Soon, Registered Professional, RHT Capital Pte. Ltd., 36 Robinson Road, #10-06 City House, Singapore 068877, sponsor@rhtgoc.com.*